XanGo Issued Key U.S. Patent for Mangosteen Dietary Supplements.

Patented Beverages and Compositions Provide Remarkable Source of Dietary Xanthones

Draper, Utah, 4 May 2004 XanGo, LLC ( www.xango.net ), the pioneer in mangosteen health supplements, today announced it has been issued a patent by the U.S. Patent Office for its proprietary dietary formulations. XanGo’s U.S. Patent number 6,730,333, titled Nutraceutical Mangosteen Composition, describes novel combinations of the mangosteen fruit in dietary compositions.

XanGo believes that receiving a patent covering our flagship XanGo beverage reinforces our position of leadership in this industry. We will continue to innovate, fueling the explosive, unparalleled growth our company has experienced, which will, in turn, provide our distributors with unique opportunities for success, said Gary Hollister, chief executive officer of XanGo.

The patent covers a wide variety of beverages, compositions, and methods of manufacturing mangosteen-based nutraceutical compositions. Although imitation is flattering, noted Bryan Davis, XanGo’s general counsel, we have a carefully designed strategy for obtaining intellectual property rights covering our innovations.

Launched in October 2002, XanGo, LLC now operates in five countries, including the United States. Our brand has always been strong. But now, with this patent, our brand is even stronger, explained Aaron Garrity, the president and chief operating officer of XanGo. We are the original, the first to market. XanGo created an entire new category of products that encourage health and wellness. This patent strengthens our position as the world leader in mangosteen-based dietary supplements.

The company, XanGo, LLC, is headquartered in Draper, Utah, with operations in Australia, New Zealand, Japan, Canada, and the United States. XanGo sells its patented XanGoâ„¢ beverage through a network of independent distributors.